EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
You can subscribe to receive the EAHP EU Monitor by email here.
.jpg)
What are we measuring in European Hospital Pharmacy?As part of its Summit project to define the future of hospital pharmacy in Europe, EAHP has launched a survey of senior pharmacists within hospitals to better understand what aspects of service are currently measured.
More information here.
The European Commission has brought together 38 organisations from 22 EU Member States, Norway and Iceland with the purpose of collecting, validating, scaling up and transferring good practices to address chronic diseases, multi-morbidity and diabetes..
The third work package of the joint action focuses on ‘the development of common guidance and methodologies for care pathways for multi-morbid patients’. The focus of this work package will be on outcome measures – interventions to promote the provision of high quality care that meets the needs of people with multimorbidity.
The Commission believe that that past actions on this issue have largely focused on analysis of the impact of multimorbidity on individuals (and healthcare systems), with very few initiatives examining which interventions have helped improve outcomes.
It is expected that the work package will provide a comprehensive review of existing work on care pathway interventions addressing multimorbid patients across EU – based on clinical evidence. It will generate a thorough repository of good practices and clinical data on the effectiveness of care interventions tackling chronic multimorbidity conditions, including polypharmacy.
The action is being led by Juan E. Riese PhD MBA of the Institute of Health Carlos III in Madrid, Spain.
More information here.
Information on the multi-morbidity work package here.
Orphan drug marketing authorisations continue to increase A total of 11 out of 81 medicines recommended for marketing authorisation by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in 2013 were intended for the treatment of rare diseases, continuing a year on year increase (8 in 2012 and 4 in 2011).
IOne of the explanations offered by the Committee for Orphan Medicinal Products (COMP), the EMA committee responsible for recommending orphan designation of medicines for rare diseases, is that developers of orphan medicines are now making much better use of the tools offered by the Agency and the European Orphan Regulation to support them in the development of their medicines.
“12 years after the European Orphan Regulation came into force, it is undoubtedly serving its purpose, with more and more orphan medicines reaching patients with rare diseases each year," explains Bruno Sepodes, Chair of the COMP.
More information here.
In other news, as part of its drive to improve the transparency of its decision making processes, the EMA have begun publishing the full minutes of the Committee for Medicinal Products for Human Use (CHMP), the Committee for Medicinal Products for Veterinary Use (CVMP) and the Committee for Advanced Therapies (CAT).
More information here.
Congress preview: hospital pharmacy into primary care Over the last few years health-care systems have begun to evolve to enhance the pharmaceutical management of patients as they move through the interfaces of care and in particular as they transit between secondary and primary care. Pharmacy related services in each sector must adapt to ensure appropriate support of patients during transfer of care.
In response to these changes, hospital pharmacists have developed services, through a process of innovation and translational research, which supports individualised pharmaceutical care and efficient drug therapy management within primary care.
The seminar at the 19th Congress of the EAHP on this subject will take place on Wednesday 26th March 2014 (2pm to 3.30pm) and Thursday 27th March (0830-1000am).
Information on the seminar here.
Information on the full Congress programme here.
.gif)
In an editorial piece for the latest edition of the European Journal of Hospital Pharmacy (EJHP), Editor-in-Chief Phil Wiffen debates the issues provoked by a 2013 Cochrane review of the role played by medication reviews.
The Editor advises: “what can seem like evidence that something does not work can often be just a lack of evidence”, going on to highlight the need for pharmacists to demonstrate effectiveness and value in the roles they perform.
A future edition of the EHJP in 2014 will focus on medicines review.
Full article here.
